Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Terns Pharmaceuticals, Inc. - Common Stock (NQ:TERN)

40.11 -0.29 (-0.72%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Terns Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer ↗
Viking Therapeutics is an upstart in the weight-loss drugs space. But it's catching attention. 
Via Investor's Business Daily
News headline image
This Small-Cap Stock Has a Promising GLP-1 Drug Which Could Rival Novo Nordisk and Eli Lilly's Weight-Loss Treatments ↗
Terns has a modest market cap of less than $800 million, and its possible upside could be massive. 
Via The Motley Fool
News headline image
Applied Therapeutics, PowerFleet, VF Corp, Victoria's Secret And Other Big Stocks Moving Higher On Wednesday ↗
 
Via Benzinga
News headline image
Missed Out on Viking Therapeutics? Buy This Weight Loss Biotech Stock Right Now. ↗
Terns Pharmaceuticals just proved that it's competitive in the weight loss field. 
Via The Motley Fool
News headline image
Top 2 Health Care Stocks That May Collapse This Quarter ↗
 
Via Benzinga
News headline image
Should You Invest in This Under-the-Radar Weight Loss Stock? ↗
Getting in on the ground floor sounds like a great idea, but not if the building ends up crumbling. 
Via The Motley Fool
News headline image
1 New Weight Loss Drug Stock to Buy Now With $1,000 and Hold for 5 Years or More ↗
This biotech's data suggests that it could have an advantage in its target market. 
Via The Motley Fool
News headline image
Terns Announces Closing of Public Offering of Shares of Common Stock and Pre-Funded Warrants, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Announces Pricing of Upsized $150.15 Million Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Calavo Growers Posts Better-Than-Expected Earnings, Joins Tesla, Oracle, Mission Produce And Other Big Stocks Moving Higher On Tuesday ↗
 
Via Benzinga
News headline image
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday ↗
 
Via Benzinga
News headline image
Terns Announces Proposed Public Offering
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals, Boeing, Tesla And Other Big Stocks Moving Higher On Monday ↗
 
Via Benzinga
News headline image
Terns Pharmaceuticals' Oral GLP-1 Reaches Phase 1 Finish Line With Encouraging Weight Loss Data After One Month ↗
Terns Pharmaceuticals announced promising Phase 1 trial results for TERN-601, showing significant weight loss in obese and overweight adults, with up to 4.9% placebo-adjusted mean weight loss at the... 
Via Benzinga
News headline image
Terns Pharmaceuticals Announces Positive Phase 1 Clinical Trial Results with TERN-601 Once-Daily Oral GLP-1R Agonist for the Treatment of Obesity
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race ↗
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
News headline image
TERN Stock Earnings: Terns Pharma Beats EPS for Q2 2024 ↗
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Terns Pharmaceuticals Reports Second Quarter 2024 Financial Results and Corporate Updates
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
3 Biotech Stocks That Could Have Investors Grinning Soon ↗
Biotech stocks are a high risk, high reward investment and these three biotechs offer significant upside potential. 
Via InvestorPlace
News headline image
Terns Pharmaceuticals Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Can These 2 Biotechs Beat Eli Lilly and Novo Nordisk in Weight-Loss Drugs? ↗
At least one of the pair has a credible shot at finding a home in the market. 
Via The Motley Fool
News headline image
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players' ↗
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
News headline image
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗
 
Via Benzinga
News headline image
Methode Electronics Posts Strong Sales, Joins QuantumScape, Ribbon Communications And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Terns Pharmaceuticals Highlights New Preclinical Data Supporting TERN-501 in Combination with a GLP-1R Agonist for Obesity at the ADA’s 84th Annual Scientific Sessions and Upcoming Conference Participation
TERN-501 significantly improved the efficacy of a GLP-1 receptor agonist by normalizing energy expenditure, resulting in greater weight loss, increased fat mass loss and relative preservation of lean... 
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Terns Pharmaceuticals to Participate in UBS Obesity Therapeutics Day
From Terns Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
TERN Stock Earnings: Terns Pharma Beats EPS for Q1 2024 ↗
TERN stock results show that Terns Pharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.